TMIGD2 is an orchestrator and therapeutic target on human acute myeloid leukemia stem cells

• Published in: Nature communications 2024-01, Vol.15 (1), p.11-11, Article 11
• Main Authors: Wang, Hao, Sica, R. Alejandro, Kaur, Gurbakhash, Galbo, Phillip M., Jing, Zhixin, Nishimura, Christopher D., Ren, Xiaoxin, Tanwar, Ankit, Etemad-Gilbertson, Bijan, Will, Britta, Zheng, Deyou, Fooksman, David, Zang, Xingxing
• Format: Article
• Language: English
• Subjects: 13/1; 13/100; 13/31; 631/250; 631/67/1990/283/1897; 692/699; 82/80; Acute myeloid leukemia; Cell differentiation; Cell proliferation; Cell self-renewal; Cyclic AMP response element-binding protein; Differentiation; Extracellular signal-regulated kinase; Hematopoiesis; Hematopoietic Stem Cells; Hemopoiesis; Humanities and Social Sciences; Humans; Immunoglobulins; Killer cells; Leukemia; Leukemia, Myeloid, Acute - drug therapy; Leukemia, Myeloid, Acute - therapy; Leukemogenesis; Lymphocytes T; Monoclonal antibodies; multidisciplinary; Neoplastic Stem Cells; Progenitor cells; Receptors; Science; Science (multidisciplinary); Signal Transduction; Stem cells; Therapeutic targets; Xenotransplantation
• ISSN: 2041-1723; 2041-1723
• DOI: 10.1038/s41467-023-43843-6

Acute myeloid leukemia (AML) is initiated and sustained by a hierarchy of leukemia stem cells (LSCs), and elimination of this cell population is required for curative therapies. Here we show that transmembrane and immunoglobulin domain containing 2 (TMIGD2), a recently discovered co-stimulatory immune receptor, is aberrantly expressed by human AML cells, and can be used to identify and enrich functional LSCs. We demonstrate that TMIGD2 is required for the development and maintenance of AML and self-renewal of LSCs but is not essential for normal hematopoiesis. Mechanistically, TMIGD2 promotes proliferation, blocks myeloid differentiation and increases cell-cycle of AML cells via an ERK1/2-p90RSK-CREB signaling axis. Targeting TMIGD2 signaling with anti-TMIGD2 monoclonal antibodies attenuates LSC self-renewal and reduces leukemia burden in AML patient-derived xenograft models but has negligible effect on normal hematopoietic stem/progenitor cells. Thus, our studies reveal the function of TMIGD2 in LSCs and provide a promising therapeutic strategy for AML. The immune receptor Transmembrane and immunoglobulin domain containing 2 (TMIGD2) mediates T-cell and nature killer cells co-stimulation upon B7-family HHLA2 engagement. Here, the authors show that TMIGD2 is expressed in Acute Myeloid Leukaemia stem cells regulating self-renewal and differentiation to facilitate leukemogenesis.